HOVEDBUDSKAP
Manglende medikamentetterlevelse er en av hovedårsakene til at pasienter med hypertensjon ikke når behandlingsmål, og dette omfatter rundt halvparten av pasienter med angivelig terapiresistent hypertensjon
Dårlig medikamentetterlevelse kan blant annet avdekkes med terapeutisk medikamentmonitorering eller direkte observert medikamentinntak med påfølgende 24 timers ambulatorisk blodtrykksmåling
Terapeutisk medikamentmonitorering kan i tillegg gi oss økt kunnskap om forskjeller i pasienters metabolisme av medikamenter
- 1.
Klouman M, Asberg A, Widerøe TE. Blodtrykksnivå i en norsk befolkning – betydningen av arv og livsstil. Tidsskr Nor Legeforen 2011; 131: 1185 – 9.
- 2.
Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31: 1281 – 357.
- 3.
Calhoun DA, Jones D, Textor S et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008; 51: 1403 – 19.
- 4.
Persu A, Jin Y, Baelen M et al. Eligibility for renal denervation: experience at 11 European expert centers. Hypertension 2014; 63: 1319 – 25.
- 5.
Fagard RH. Resistant hypertension. Heart 2012; 98: 254 – 61.
- 6.
The 1988 report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1988; 148: 1023 – 38.
- 7.
Klein LE. Compliance and blood pressure control. Hypertension 1988; 11: II61 – 4.
- 8.
Fadl Elmula FE, Hoffmann P, Larstorp AC et al. Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment-resistant hypertension. Hypertension 2014; 63: 991 – 9.
- 9.
Fadl Elmula FE, Hoffmann P, Fossum E et al. Renal sympathetic denervation in patients with treatment-resistant hypertension after witnessed intake of medication before qualifying ambulatory blood pressure. Hypertension 2013; 62: 526 – 32.
- 10.
Brinker S, Pandey A, Ayers C et al. Therapeutic drug monitoring facilitates blood pressure control in resistant hypertension. J Am Coll Cardiol 2014; 63: 834 – 5.
- 11.
Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005; 353: 487 – 97.
- 12.
Burnier M, Wuerzner G, Struijker-Boudier H et al. Measuring, analyzing, and managing drug adherence in resistant hypertension. Hypertension 2013; 62: 218 – 25.
- 13.
Culig J, Leppée M. From Morisky to Hill-bone; self-reports scales for measuring adherence to medication. Coll Antropol 2014; 38: 55 – 62.
- 14.
Dicarlo L, Naik R, Macey N. An ingestible sensor and wearable patch tracking adherence and activity patterns identified underlying factors leading of persistent hypertension: a real-world registry study. London: European Society of Cardiology Congress, 2015.
- 15.
Belknap R, Weis S, Brookens A et al. Feasibility of an ingestible sensor-based system for monitoring adherence to tuberculosis therapy. PLoS One 2013; 8: e53373.
- 16.
Garfield S, Clifford S, Eliasson L et al. Suitability of measures of self-reported medication adherence for routine clinical use: a systematic review. BMC Med Res Methodol 2011; 11: 149.
- 17.
Wejse C. Tuberculosis elimination in the post Millennium Development Goals era. Int J Infect Dis 2015; 32: 152 – 5.
- 18.
Sørensen H, Fadl Elmula FE, Kjeldsen SE et al. Renal sympatisk denervering ved terapiresistent hypertensjon. Tidsskr Nor Legeforen 2014; 134: 32 – 6.
- 19.
Eskås PA, Heimark S, Fadl Elmula FE et al. Non-adherence revealed by witnessed intake of antihypertensive drugs prior to ambulatory blood pressure monitoring was the main reason for non-eligibility in the Oslo RDN study. J Hypertens 2015; 33: PP.26.28.
RE: Medikamentetterlevelse og monitorering av antihypertensi
16.08.2016Takk for en meget interessant og relevant oversiktsartikkel, der en blant annet omtaler nytten av terapeutisk legemiddelmonitorering som virkemiddel for å fremme legemiddeletterlevelse hos pasienter som behandles med antihypertensiva (1). Behov for kontroll av…